1. Home
  2. SSP vs AKBA Comparison

SSP vs AKBA Comparison

Compare SSP & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo E.W. Scripps Company (The)

SSP

E.W. Scripps Company (The)

HOLD

Current Price

$2.75

Market Cap

264.6M

Sector

Industrials

ML Signal

HOLD

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.01

Market Cap

251.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSP
AKBA
Founded
1878
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
264.6M
251.0M
IPO Year
1998
2014

Fundamental Metrics

Financial Performance
Metric
SSP
AKBA
Price
$2.75
$1.01
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$6.95
$4.67
AVG Volume (30 Days)
574.7K
5.3M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
93.94
EPS
N/A
N/A
Revenue
$2,150,585,000.00
N/A
Revenue This Year
$8.34
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.04
$0.82
52 Week High
$5.39
$4.08

Technical Indicators

Market Signals
Indicator
SSP
AKBA
Relative Strength Index (RSI) 29.81 48.17
Support Level $2.73 $0.85
Resistance Level $3.01 $1.56
Average True Range (ATR) 0.21 0.07
MACD -0.04 0.02
Stochastic Oscillator 21.37 74.74

Price Performance

Historical Comparison
SSP
AKBA

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: